Combination chemotherapy for human immunodeficiency virus-1

American Journal of Medicine

Volumn 102, Issue 5 B, 1997, Pages 76-80

  Manion, Douglas J ^a   Hirsch, Martin S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG POTENTIATION; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; PROPHYLAXIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS;

EID: 0030833565     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00068-5     Document Type: Conference Paper

References (34)

1. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during clinically latent stage of disease. Nature. 1993;362:355-358.
2. Cao Y, Ho DD, Todd J, et al. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Human Retrovir. 1995;11:353-361.
3. Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med. 1991;324:954-960.
4. Ho DD. Viral counts in HIV infection. Science. 1996;272:1124-1125.
5. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-1586.
6. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM. Rapid turnover of plasma virons and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
7. Johnson VA, Merrill DP, Videler JA, et al. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis. 1991;164:646-655.
8. Collier AC, Coombs RW, Fischl MA, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med. 1993;119:786-793.
9. Shafer RW, Iversen AK, Winters MA, et al. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis. 1995;172:70-78.
10. Meng TC, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med. 1992;116:13-20.
11. + cells per cubic millimeter. North American HIV Working Party. N Engl J Med. 1995;333:1662-1669.
12. Merrill DP, Moonis M, Chou TC, Hirsch MS. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis. 1996;173:355-364.
13. 3 and greater than 12 weeks zidovudine experience. ACTG 290 interim review results, 1996.
14. Mazzulli T, Rusconi S, Merrill DP, et al. Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrob Agents Chemother. 1994;38:656-661.
15. Rusconi S, Merrill DP, Hirsch MS. Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy. J Infect Dis. 1994;170:1361-1366.
16. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;124:1019-1030.
17. Gulick R, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC). 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC, 1996.
18. Montaner J. Preliminary report of BI 1046. Paper presented at University of Amsterdam and Antiviral Therapy meeting, Can HIV Be Eradicated From an Infected Individual? Washington, DC, June 12-13, 1996.
19. Hammer S, Katzenstein D, Hughes M, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996;335:1081-1090.
20. Katzenstein D, Hammer S, Hughes M, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med. 1996;335:1091-1098.
21. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet. 1996l348:283-291.
22. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients wth the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. 1996;335:1099-1106.
23. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA. 1996;276:118-125.
24. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995;269:696-699.
25. Chow YK, Hirsch MS, Merrill DP, et al. Use of evolutiona-y limitations of HIV-1 multidrug resistance to optimize therapy. Nature. 1993;361:650-654.
26. Johnson VA, Merrill DP, Chou TC, Hirsch MS. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. J Infect Dis. 1992;166:1143-1146.
27. Chokekijchai S, Shirasaka T, Weinstein JN, Mitsuya H. In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddl. Antiviral Res. 1995;28:25-38.
28. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med. 1996;334:1011-1017.
29. 3) in patients discontinuing or unable to take retrovir. Executive summary NV14256 - clinical endpoint analysis. 1996.
30. 3. 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, 1997.
31. 3 and >3 months of prior ZDV experience. Executive summary ACTG 320, 1997.
32. Cameron W, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC, 1996.
33. Centers for Disease Control and Prevention. Provisional public health service recommendations for chemoprophylaxis after occupational exposure to HIV-1. MMWR 1996;45:468-472.
34. Carpenter CCJ, Fischl MA, Hammer S, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA. 1996;276:146-154.